Elarofiban TFA

CAS No. 198958-89-3

Elarofiban TFA( —— )

Catalog No. M34234 CAS No. 198958-89-3

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 321 In Stock
10MG 459 In Stock
25MG 718 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Elarofiban TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
  • Description
    Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    198958-89-3
  • Formula Weight
    644.56
  • Molecular Formula
    C26H34F6N4O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC(C(F)(F)F)=O.O=C([C@H]1CN(CCC1)C(CCC2CCNCC2)=O)N[C@H](C3=CN=CC=C3)CC(O)=O.OC(C(F)(F)F)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • RBC8

    RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.

  • Tirofiban hydrochlor...

    A potent, selective inhibitor of the platelet fibrinogen receptor GPIIb/IIIa with IC50 of 9 nM.

  • ALG1001

    ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis.